TY - JOUR T1 - Lung cancer screening provides an opportunity for early diagnosis and treatment of interstitial lung disease JF - Thorax JO - Thorax SP - 1149 LP - 1151 DO - 10.1136/thorax-2022-219068 VL - 77 IS - 11 AU - Richard J Hewitt AU - Emily C Bartlett AU - Rea Ganatra AU - Haroun Butt AU - Vasilis Kouranos AU - Felix Chua AU - Maria Kokosi AU - Philip L Molyneaux AU - Sujal R Desai AU - Athol U Wells AU - R Gisli Jenkins AU - Elisabetta A Renzoni AU - Samuel V Kemp AU - Anand Devaraj AU - Peter M George Y1 - 2022/11/01 UR - http://thorax.bmj.com/content/77/11/1149.abstract N2 - Interstitial lung abnormalities (ILA) can be incidentally detected in patients undergoing low-dose CT screening for lung cancer. In this retrospective study, we explore the downstream impact of ILA detection on interstitial lung disease (ILD) diagnosis and treatment. Using a targeted approach in a lung cancer screening programme, the rate of de novo ILD diagnosis was 1.5%. The extent of abnormality on CT and severity of lung function impairment, but not symptoms were the most important factors in differentiating ILA from ILD. Disease modifying therapies were commenced in 39% of ILD cases, the majority being antifibrotic therapy for idiopathic pulmonary fibrosis. ER -